Log In
Print this Print this

Descovy, emtricitabine/tenofovir alafenamide (F/TAF)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionFixed-dose combination of emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide (TAF), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir
Molecular Target HIV reverse transcriptase
Mechanism of ActionHIV reverse transcriptase inhibitor; Nucleoside analog reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV-1 infection in patients >=12 years old, in combination with other HIV antiretroviral agents
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today